Healthcare Pharmaceuticals Ltd, one of the largest pharmaceutical companies in Bangladesh, has launched Eli Lilly & Company’s Humalog® 200 for diabetes treatment in Bangladesh.
Humalog® 200 (Insulin Lispro 200 Units/ml) KwikPen®) is the concentrated, rapid acting analogue insulin designed to improve blood sugar control in adults with both Type 1 and Type 2 diabetic.
Humalog® 200 is US-Food and drug Administration approved medicine and manufactured by Eli Lilly & Company, said the company in a statement on Saturday.
Over time, some diabetic patients may require dosage increase of their insulin for improved glycaemic control.
Patients, who are obese, have high insulin resistance and require large daily dose of mealtime insulin, Humalog® 200 could be comfortable option for them, according to the statement.
Clinical studies done on Humalog® 200 have established equivalent efficacy & safety versus conventional 100-unit insulin but with half the volume which is a preferred need for patients.
Humalog® 200 comes in an easy to use - KwikPen® that holds twice as many insulin units and requires fewer pen changes every month, thus it offers cost-effectiveness to the patients as well.
This pen is easier to use and administer the injection. Humalog® 200 KwikPen® is suitable for the patients searching for convenient and comfortable mealtime intensification options.
“Diabetes is a big burden on the healthcare system in Bangladesh. More than 13 million people live with diabetes in the country and their treatments are individualized. The launch of Humalog® 200 will open newer avenues in diabetes management and provide health care professionals a better way to manage diabetes” said Halimuzzaman, DMD & CEO of Healthcare Pharmaceuticals,at the launching event.
Humalog®200 will be marketed and distributed in Bangladesh by Healthcare Pharmaceuticals, a leading life science organization that believes in innovation, patient benefit and compliance, he said.
Lilly and Healthcare Pharmaceuticals entered into an Agreement for distribution and promotion of Lilly products in Bangladesh. Humalog U200 KwikPen® is a valuable addition to the Lilly Diabetes portfolio in the country given the increasing burden of diabetes in Bangladesh.
“Type 2 diabetes is a progressive disease and in Bangladesh many patients do not meet their treatment goals. Humalog® 200 is new, concentrated rapid acting analogue insulin that has been designed keeping patients’ needs and convenience in mind,” said Prof. A K Azad Khan, President of Diabetic Association of Bangladesh (BADAS).
Humalog® 200 is a prescription drug that should be taken only on advice from registered physicians who deal with diabetic patients. When prescribed, it should be used as an adjunct to diet and exercise.
Healthcare Pharmaceuticals is one of the largest companies in the pharmaceutical industry in Bangladesh manufacturing branded generic products for local and overseas market in Asia, Africa and CIS region.
The drug manufacturer had started developing its factory & now manufacturing more than 300 products with all types of dosage forms and distributing throughout Bangladesh with a Sales Force of 2100 with a remarkable business growth in the industry.
